Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3SP9

Structural basis for iloprost as a dual PPARalpha/delta agonist

3SP9 の概要
エントリーDOI10.2210/pdb3sp9/pdb
関連するPDBエントリー3SP6
分子名称Peroxisome proliferator-activated receptor delta, (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S,4R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid (3 entities in total)
機能のキーワードnuclear receptor lbd, nuclear receptor fold, ligand binding, gene transcription, drug binding, transcription
由来する生物種Homo sapiens (human)
細胞内の位置Nucleus: Q03181
タンパク質・核酸の鎖数2
化学式量合計65179.78
構造登録者
Rong, H.,Li, Y. (登録日: 2011-07-01, 公開日: 2011-07-20, 最終更新日: 2024-02-28)
主引用文献Jin, L.,Lin, S.,Rong, H.,Zheng, S.,Jin, S.,Wang, R.,Li, Y.
Structural basis for iloprost as a dual peroxisome proliferator-activated receptor alpha/delta agonist.
J.Biol.Chem., 286:31473-31479, 2011
Cited by
PubMed Abstract: Iloprost is a prostacyclin analog that has been used to treat many vascular conditions. Peroxisome proliferator-activated receptors (PPARs) are ligand-regulated transcription factors with various important biological effects such as metabolic and cardiovascular physiology. Here, we report the crystal structures of the PPARα ligand-binding domain and PPARδ ligand-binding domain bound to iloprost, thus providing unambiguous evidence for the direct interaction between iloprost and PPARs and a structural basis for the recognition of PPARα/δ by this prostacyclin analog. In addition to conserved contacts for all PPARα ligands, iloprost also initiates several specific interactions with PPARs using its unique structural groups. Structural and functional studies of receptor-ligand interactions reveal strong functional correlations of the iloprost-PPARα/δ interactions as well as the molecular basis of PPAR subtype selectivity toward iloprost ligand. As such, the structural mechanism may provide a more rational template for designing novel compounds targeting PPARs with more favorable pharmacologic impact based on existing iloprost drugs.
PubMed: 21775429
DOI: 10.1074/jbc.M111.266023
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.3 Å)
構造検証レポート
Validation report summary of 3sp9
検証レポート(詳細版)ダウンロードをダウンロード

250059

件を2026-03-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon